Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
This article was originally published in The Gray Sheet
Executive Summary
diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease